A London-based health technology startup founded by a former Palantir executive has raised £9.7m in a funding round led by Atomico, the European venture capital firm, with participation from XYZ Venture Capital and Firstminute Capital. The company, Frontier Health, has now raised £11.9m in total since its founding in 2024.

Rachel Finegold, who was Palantir's healthcare lead for 40 NHS hospitals during the Covid-19 outbreak, launched the company. That experience, she has said, gave her direct sight of how administrative processes affect the movement of patients through the health system. "There physically weren't enough administrators to support this integral machinery that needs to happen to keep patients moving through the system and to get patients their care," Finegold said.

The problem Frontier Health is trying to address is not a small one. Healthcare systems globally are projected to face a shortfall of ten million workers by 2030, and the company argues that reducing the administrative burden on clinical and non-clinical staff is one of the more tractable ways to close that gap. Within the NHS specifically, administrative tasks have long been identified as a drag on capacity, consuming staff time that might otherwise be directed toward patient care.

Frontier Health's product is an AI agent called Juno, which is designed to work alongside NHS administrative teams rather than replace them. Juno can help staff navigate internal systems, complete routine tasks such as booking appointments, flag potential risks in patient pathways and support the coordination of care across departments. If the agent encounters a situation it cannot handle, it is designed to escalate to a human member of staff. East Sussex Healthcare NHS Trust is listed on the company's website as a client.

The new funding will be used to extend Frontier Health's presence across NHS trusts in England and to grow its current team of twelve. Neither a schedule for growth nor particular recruiting goals have been revealed by the firm.

The investment comes at a moment of heightened interest in AI applications across the NHS, but also against a complicated backdrop for one of the sector's most prominent technology suppliers. Palantir, the US data analytics company, currently provides software used by more than half of NHS trusts in England to help manage waiting lists. The British Medical Association has called on the NHS to end its relationship with Palantir, pointing to the company's contracts with US Immigration and Customs Enforcement as the basis for its concern.

Finegold's prior role at Palantir gives Frontier Health an unusual vantage point in that debate, though the company's focus is on administrative workflow rather than the kind of large-scale data infrastructure Palantir provides. Whether that distinction will matter to NHS procurement teams remains to be seen.

Atomico, the lead investor in the funding round, said it believes AI of this kind could become critical infrastructure for health systems operating under sustained pressure. "As healthcare systems face growing demand and limited resources, we believe supportive AI can become critical infrastructure, augmenting frontline teams and improving care delivery," the firm stated.

The appetite for that kind of investment is clear. What is less certain is whether AI agents can deliver the operational improvements at scale that their backers are anticipating, particularly within an NHS procurement environment that has historically been slow to adopt and integrate new technology. Frontier Health is at an early stage, with one named trust and a small team. The next phase will test whether the problem Finegold identified during the pandemic years can be addressed at the pace the funding now requires.